MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11684-021-0850-9

Медицинская библиотека · Frontiers of medicine · 2021

Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension.

Wang Huai-Yu, Peng Suyuan, Ye Zhanghui, Li Pengfei, Li Qing, Shi Xuanyu, Zeng Rui, Yao Ying, He Fan, Li Junhua, Liu Liu, Ge Shuwang, Ke Xianjun, Zhou Zhibin, Xu Gang, Zhao Ming-Hui, Wang Haibo, Zhang Luxia, Dong Erdan

СтатьяПеревод в очереди

Аннотация

Consecutively hospitalized patients with confirmed coronavirus disease 2019 (COVID-19) in Wuhan, China were retrospectively enrolled from January 2020 to March 2020 to investigate the association between the use of renin-angiotensin system inhibitor (RAS-I) and the outcome of this disease. Associations between the use of RAS-I (angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)), ACEI, and ARB and in-hospital mortality were analyzed using multivariate Cox proportional hazards regression models in overall and subgroup of hypertension status. A total of 2771 patients with COVID-19 were included, with moderate and severe cases accounting for 45.0% and 36.5%, respectively. A total of 195 (7.0%) patients died. RAS-I (hazard ratio (HR)= 0.499, 95% confidence interval (CI) 0.325-0.767) and ARB (HR = 0.410, 95% CI 0.240-0.700) use was associated with a reduced risk of all-cause mortality among patients with COVID-19. For patients with hypertension, RAS-I and ARB applications were also associated with a reduced risk of mortality with HR of 0.352 (95% CI 0.162-0.764) and 0.279 (95% CI 0.115-0.677), respectively. RAS-I exhibited protective effects on the survival outcome of COVID-19. ARB use was associated with a reduced risk of all-cause mortality among patients with COVID-19.

Для цитирования: Wang Huai-Yu, Peng Suyuan, Ye Zhanghui, Li Pengfei, Li Qing, Shi Xuanyu, Zeng Rui, Yao Ying, He Fan, Li Junhua, Liu Liu, Ge Shuwang, Ke Xianjun, Zhou Zhibin, Xu Gang, Zhao Ming-Hui, Wang Haibo, Zhang Luxia, Dong Erdan. Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension.. Frontiers of medicine. 2021. DOI: 10.1007/s11684-021-0850-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.